Pfizer's Melanoma Drug Gets New Lease On Phase III Life With Debiopharm Deal
Analysis of prior Phase III failure helped identify patients who will respond to the cancer immunotherapy tremelimumab.
Analysis of prior Phase III failure helped identify patients who will respond to the cancer immunotherapy tremelimumab.